Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Bliss Biopharma Out-Licenses HER2 ADC to Eisai for up to $2 Billion

publication date: May 8, 2023

Bliss Biopharma (Hangzhou), a clinical-stage ADC company, may out-license global rights (ex-China) for its HER2 ADC to Japan’s Eisai Pharma in a deal with a potential value of $2 billion. Initially, the two companies are collaborating on conducting Phase I/II clinical trials of the candidate, an eribulin-payload based ADC aimed at HER2 to treat cancers. Longer-term, Eisai holds an option to acquire rights to the drug, which would trigger the upfront and milestone payments. The HER2 ADC area is hot: four years ago, AstraZeneca in-licensed Daiichi Sankyo’s HER2 ADC candidate for $1 billion in staged upfront payments. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital